Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States
Haley CA, Macias P, Jasuja S, Jones BA, Rowlinson MC, Jaimon R, Onderko P, Darnall E, et al. (12 authors)
Emerging infectious diseases · 2020-11
Abstract
The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose.
MeSH terms
- Humans
- Tuberculosis
- Tuberculosis, Multidrug-Resistant
- Antitubercular Agents
- South Africa
- United States
- Diarylquinolines
- Linezolid